EUVIMEDEUVIMED entdecken
Crossref

Distribution of KRAS and BRAF mutations in Moroccan patients with advanced colorectal cancer

N Marchoudi, H Amrani Hassani Joutei, F Jouali, J Fekkak, H Rhaissi

Pathologie Biologie · 2013-12 · 61 (6) · 273-276

DOI: 10.1016/j.patbio.2013.05.004 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Pathologie Biologie, 2013-12. Verfasst von N Marchoudi und 4 weiteren Autor:innen. Beteiligte Einrichtung: Laboratoire de génétique et biologie moléculaire, faculté des sciences Ben'Msik-Bd Driss Elharti, BP 79, 55, Sidi Othman, Casablanca, Morocco; Départ…. Hauptthemen laut MEDLINE: Mutation. Die Arbeit wurde bisher 22-mal zitiert (Crossref) und nennt 25 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Targeted therapies have an increasing importance in digestive oncology. To our knowledge, we are the first to report the distribution of KRAS and BRAF mutations in Moroccan patients with advanced colorectal cancer (CRC) in order to introduce targeted therapy in the arsenal of therapeutic modalities for management of this cancer in Morocco. In this study, 92 samples obtained from patients with CRC were tested for the presence of the nine most common mutations in the KRAS gene and BRAF gene. Among the tested patients, 76.09% of patients had wt-KRAS genotype and 23.91% were KRAS mutants and the majority of mutations would result in an amino acid substitution of glycine by aspartic acid (68.2%) The predominant mutations are G>A transitions and G>T transversions. Around 5% (5.43%) of the tested patients bore the V600E mutation in BRAF gene. Only one patient showing to have the V600E mutation in BRAF was also mutated-KRAS. Summing up the results about the KRAS and the BRAF mutation carriers from our study, the portion of potentially non responsive patients for the anti-EGFR treatment is 28.26%.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

MutationAdultAgedAged, 80 and overColorectal NeoplasmsDisease ProgressionDrug Resistance, NeoplasmErbB ReceptorsFemaleGene FrequencyHumansMaleMiddle AgedMoroccoPolymorphism, Single NucleotideProtein Kinase InhibitorsProto-Oncogene ProteinsProto-Oncogene Proteins B-rafProto-Oncogene Proteins p21(ras)ras Proteins

Stichwörter der Autor:innen

BRAF mutationCancer colorectalColorectal cancerKRAS mutationMutation du BRAFMutation du KRAS

Substanzen

KRAS protein, humanProtein Kinase InhibitorsProto-Oncogene ProteinsEGFR protein, humanErbB ReceptorsBRAF protein, humanProto-Oncogene Proteins B-rafProto-Oncogene Proteins p21(ras)ras Proteins

Autor:innen und Institutionen

  • Laboratoire de génétique et biologie moléculaire, faculté des sciences Ben'Msik-Bd Driss Elharti, BP 79, 55, Sidi Othman, Casablanca, Morocco; Département de biologie moléculaire, centre spécialisé des analyses médicale…

Zitieren

APA

Marchoudi, N., Amrani Hassani Joutei, H., Jouali, F., Fekkak, J., & Rhaissi, H. (2013). Distribution of KRAS and BRAF mutations in Moroccan patients with advanced colorectal cancer. Pathologie Biologie, 61(6), 273-276. https://doi.org/10.1016/j.patbio.2013.05.004

Vancouver

Marchoudi N, Amrani Hassani Joutei H, Jouali F, Fekkak J, Rhaissi H. Distribution of KRAS and BRAF mutations in Moroccan patients with advanced colorectal cancer. Pathologie Biologie. 2013;61(6):273-276. doi:10.1016/j.patbio.2013.05.004

BibTeX
@article{Marchoudi2013,
  author = {Marchoudi, N and Amrani Hassani Joutei, H and Jouali, F and Fekkak, J and Rhaissi, H},
  title = {Distribution of KRAS and BRAF mutations in Moroccan patients with advanced colorectal cancer},
  journal = {Pathologie Biologie},
  year = {2013},
  volume = {61},
  number = {6},
  pages = {273--276},
  doi = {10.1016/j.patbio.2013.05.004}
}
Kostenlos starten →